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Abstract Drug-induced QT prolongation is a potentially
dangerous adverse effect of some medication combinations.
When QT prolongation progresses to torsade de pointes,
life-threatening or fatal outcomes may result. A 57-year-old
man with a history of human immunodeficiency syndrome
on abacavir, nevirapine, tenofovir, voriconazole, and
methadone presented to the emergency department with a
chief complaint of new-onset seizures. The physical exam
was unremarkable. The electrocardiogram demonstrated
sinus bradycardia and a prolonged QTc interval of 690
ms. In the emergency department, he had several episodes
of torsade de pointes (TdP) and ventricular tachycardia that
resolved spontaneously. These episodes were accompanied
by an alteration in mentation and generalized twitching.
Magnesium and amiodarone were effective in terminating
the dysrhythmia. The patient had multiple risk factors for
prolonged QT syndrome including human immunodefi-
ciency virus infection, methadone therapy, and polyphar-
macy leading to potential drug interactions. Physicians
must be aware of multidrug interactions potentiating QT
prolongation and leading to torsade de pointes.
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Introduction
Torsade de pointes (TdP) is a life-threatening dysrhythmia
that can result from long QT syndrome. Many medica-
tions and medical conditions cause acquired long QT
syndrome. We present a case of TdP caused by a pro-
longed QT associated with polypharmacy and substance
abuse in a patient with human immunodeficiency virus
(HIV) infection. Methadone is the most widely used
medication worldwide for drug replacement therapy in
illicit drug users according to the World Health Organi-
zation [1]. The global incidence of HIV is estimated to be
33 million [2]. It is important that physicians be aware of
possible complications of interactions between these com-
mon elements.
Case report
A 57-year-old male with HIV (CD4+ count 339/µl, viral
load unknown), right lower extremity amputation, retro-
orbital aspergillosis, and a history of intravenous drug
abuse presented to the emergency department with a chief
complaint of seizures. The patient reported two episodes of
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muscle twitching and urinary incontinence without loss of
consciousness. He reported numerous episodes of palpita-
tions and shortness of breath over the past several days.
He denied weakness, syncope, fever, dizziness, chest pain,
and postictal periods. Two days prior he had been started
on highly active antiretroviral therapy with abacavir
(600 mg qd), nevirapine (200 mg qd), and tenofovir
(300 mg qd). His medication regimen also included
voriconazole (200 mg b.i.d.) for a retro-orbital aspergillo-
sis infection diagnosed 6 months prior and methadone
(125 mg/day) for detoxification of heroin addiction. He
reported current use of tobacco, marijuana and alcohol,
and remote cocaine use.
Initial vital signs were temperature 98.0°F, pulse 60
beats per minute (bpm), blood pressure 126/61 mmHg,
respiratory rate 20 breaths per minute, and oxygen saturation
98% without supplemental oxygen. He was awake, alert, and
oriented. Notable findings on physical exam were a 3/6
holosystolic murmur and right lower extremity amputation.
The rest of his exam was unremarkable.
Cardiac monitoring revealed bradycardia with heart rates
ranging from 30 to 60 bpm. Frequent polymorphic
premature ventricular beats and nonsustained ventricular
tachycardia were present. The electrocardiogram (ECG)
showed sinus rhythm at a rate of 79 bpm with a right
bundle branch block and a left anterior fascicular block
(Fig. 1). The QT interval was prolonged. The corrected QT
interval (QTc using Bazett’s formula) was 690 ms. A
baseline ECG from 5 months prior revealed sinus brady-
cardia at a rate of 51 bpm, similar bundle branch blocks,
and a QTc of 440 ms.
Laboratory results showed an unremarkable complete
blood count and serum chemistries with a potassium
of 3.7 mmol/l (reference 3.5–5.3 mmol/l), a magnesium of
0.9 mmol/l (0.53–1.03 mmol/l), and calcium of
2.15 mmol/l (2.12–2.62 mmol/l). Troponin I was indetermi-
nate at 0.7 µg/l. Head computed tomography scan was
unremarkable. Chest X-ray revealed mild pulmonary edema
with cardiomegaly.
While awaiting admission, the patient experienced
several episodes of TdP and ventricular tachycardia. Each
episode lasted 1–2 min and resolved spontaneously. During
these episodes the patient was unable to communicate
verbally, but did not lose consciousness. He exhibited
myoclonic muscle twitching and was incontinent of urine.
These episodes were similar to those he had experienced
earlier in the day. Treatment was started with 2 g of
magnesium. A bolus of amiodarone was given, followed by
a continuous infusion. Once therapy was started, the patient
had no additional episodes.
In the cardiac care unit, overdrive pacing was initiated.
An isoproterenol infusion was titrated to maintain a heart
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rate of 90 bpm to prevent reoccurrence of TdP. The patient
was continued on methadone to prevent withdrawal;
voriconazole and his antiretroviral medications were held.
Urine drug screening was positive for marijuana and
cocaine. A pacemaker/implantable cardioverter defibrillator
(ICD) was placed. After the placement of the ICD,
voriconazole was restarted.
He was discharged 12 days after admission with
resolution of his symptoms but persistent QTc prolongation.
The patient was maintained on the same medications that he
was taking prior to presentation. He was scheduled to taper
his methadone dose in the hope of discontinuing methadone
completely. Interrogation of the ICD 1 month after
discharge revealed no further episodes of TdP.
Discussion
There are two types of long QT syndrome: congenital and
acquired. Myocardial repolarization abnormalities lead to
QT prolongation on the surface ECG. This leads to an
increased risk of polymorphic ventricular tachycardia
known as torsade de pointes (TdP). Congenital causes are
secondary to genetic abnormalities of myocardial ion
channels [3]. Acquired long QT syndrome has many causes
including medication, HIV, intracranial pathology, electro-
lyte abnormalities, and renal and hepatic failure. Drugs
cause most cases of acquired long QT by inhibiting delayed
rectifier potassium channels, leading to prolonged myocar-
dial repolarization [4]. The most common inciting drugs are
antidysrhythmics and psychiatric drugs [5]. Illicit drugs
such as cocaine are another cause. The two forms of long
QT overlap. Patients with subclinical or unrecognized long
QT are at increased risk for development of TdP when
started on medications that prolong the QT interval.
The QT segment is considered abnormal when the QTc
is >440 ms in males or >460 ms in females. Drug-induced
TdP is most likely to occur with a 25% increase in the
baseline QT interval or if the QTc is >500 ms. Greater than
90% of TdP occurs when the QTc is >500 ms [4]. The
development of TdP occurs when an early afterdepolari-
zation follows a long RR interval. An early afterdepola-
rization is an impulse that occurs before the myocardial
cell has repolarized, during phase 2 or 3 of the action
potential. This leads to abnormal dispersion of myocardial
repolarization which can cause the development of a
reentrant circuit. This is the reason that TdP in acquired
long QT syndrome is referred to as pause-dependent
ventricular tachycardia. Bradycardia is therefore a risk
factor for the development of TdP. The QT interval
becomes longer as the heart rate decreases. TdP is usually
self-terminating but can lead to sustained ventricular
tachycardia and death [6].
This patient had at least four risk factors for QT
prolongation. These included HIV infection, cocaine use,
and treatment with methadone and voriconazole. HIV
infection has been shown to be an independent risk factor
for QT prolongation. Kocheril et al. showed a prevalence of a
prolonged QT in 28.6% of hospitalized HIV patients
compared with 7.0% of hospitalized patients without HIV
infection [7]. Although the pathophysiology behind this is
unclear, hypotheses include myocarditis and autonomic
neuropathies [8].
Cocaine blocks the delayed rectifier potassium channel
and has been shown to lengthen the QT interval [5, 9].
Cocaine use may have been the precipitating factor causing
torsade in this patient. It is difficult to ascertain the time
course as he refused to acknowledge recent cocaine use
despite positive urine toxicology.
Many studies have shown that methadone increases the
QT interval and may lead to TdP [10–14]. As a result, a
black box warning for methadone was issued in 2006 by
the US Food and Drug Administration, alerting practi-
tioners to the increased risk of TdP particularly in patients
with drug interactions. High-dose methadone regimens may
place patients at increased risk of TdP. In animal models,
methadone has been shown to affect the action potential by
decreasing the rate of depolarization and increasing the
action potential duration. It has also been shown to have
negative chronotropic effects that may lead to bradycardia
[10, 14]. Maremmani et al. found that 83% of patients in a
methadone maintenance program had QT prolongation
[11]. Additionally, patients on methadone are at higher risk
for TdP when given other QT-prolonging drugs or when
hypokalemic [12]. A methadone level was not obtained.
Little is known about the correlation between an elevated
methadone level and the onset of cardiac toxicity.
Voriconazole has been reported to cause QT prolonga-
tion and TdP. Voriconazole is a potent blocker of the P450
system, leading to increased concentrations of drugs
metabolized by this system. It specifically inhibits the
CYP2C19, CYP2C9, and CYP3A4 enzymes that metabo-
lize methadone. The maximum plasma concentration of
methadone can be increased by 65%. The prescribing
information states that voriconazole in combination with
methadone may lead to increased plasma concentrations of
methadone and QT prolongation. Careful monitoring is
recommended as a reduced dose of methadone may be
necessary [15].
Some protease inhibitors have been shown to prolong the
QT interval; however, this patient was not on a protease
inhibitor and QT prolongation from other antiretrovirals has
not been reported.
Treatment of acquired QT syndrome consists of removal
of the offending agents. Electrolyte abnormalities should be
corrected. Serum potassium should be maintained between
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4.5 and 5.0 mmol/l. Magnesium is the first-line therapy; 2 g
of magnesium may be given and repeated if necessary.
Overdrive pacing and isoproterenol can be titrated to keep
the heart rate >90 bpm. This will shorten the QT interval.
Implantable cardioverter defibrillator devices do not de-
crease the number of arrhythmias, but can be lifesaving if
events occur [4]. Antidysrythmics may also be used. In this
patient, amiodarone was given following the advanced
cardiac life support protocol for ventricular tachycardia in a
patient with a pulse. There is little guidance in the literature
to suggest which antidysrhythmic is the most effective
agent in drug-induced TdP. Consideration should be given
to the metabolism of amiodarone by CYP3A4 and also its
risk of QTc prolongation, though the incidence of associ-
ated TdP is less than 1% [16].
Conclusion
HIV infection and substance abuse are global problems.
Methadone maintenance is the most commonly used drug
replacement therapy for opioid dependence worldwide.
Patients with HIV and substance abuse are likely to have
other comorbidities and may be on multiple medications.
Methadone-associated TdP in the setting of methadone
therapy often occurs with the addition of another QT-
prolonging agent. Physicians must be aware of QT
prolongation secondary to methadone therapy and the drug
interactions that may potentiate toxicity from methadone.
Torsade de pointes should be included in the differential
diagnosis when evaluating patients on methadone, espe-
cially those complaining of syncope or seizures. Practi-
tioners should be aware of associated risk factors for QT
prolongation in these patients including concomitant HIV
infection or cocaine use.
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